Pharmacological Optimization of PSMA-Based Radioligand Therapy
Biomedicines, 2022 Prostate cancer (PCa) is the most common malignancy in men of middle and older age. The standard treatment strategy for PCa ranges from active surveillance in low-grade, localized PCa to radical prostatectomy, external beam radiation therapy, hormonal ...
Suzanne van der Gaag +5 more
doaj +4 more sources
161Tb-PSMA radioligand therapy in prostate cancer: current evidence and future perspectives [PDF]
Frontiers in OncologyProstate-specific membrane antigen (PSMA), a type II transmembrane glycoprotein, is overexpressed on the membranes of prostate cancer cells. Lutetium-177 (177Lu)- labelled PSMA-targeted radioligand therapy (PRLT) is employed in treating metastatic ...
Liming Xiao +13 more
doaj +2 more sources
Intra-Arterial Radioligand Therapy in Brain Cancer: Bridging Nuclear Medicine and Interventional Neuroradiology [PDF]
DiagnosticsRecurrent brain tumors—including high-grade gliomas, brain metastases, and aggressive meningiomas—continue to carry a poor prognosis, with high mortality despite therapeutic advances.
Federico Sabuzi +5 more
doaj +2 more sources
PSMA-Directed Radioligand Therapy for Metastatic Prostate Cancer
healthbook TIMES. Oncology Hematology, 2023 Prostate cancer is the leading cause of total years of life lost due to cancer in men, despite developments in treatment and technology. Improved outcomes and novel therapy concepts, such as theranostics, are urgently needed.
Ellen Heitlinger
doaj +2 more sources
Combination of Radioligand Therapy and Immunotherapy: How to Make It Work in Clinic? [PDF]
ImmunoTargets and TherapyRubin Jiao, Ekaterina Dadachova College of Pharmacy and Nutrition, University of Saskatchewan, Saskatoon, SK, CanadaCorrespondence: Ekaterina Dadachova, College of Pharmacy and Nutrition, University of Saskatchewan, 107 Wiggins Road, Health Sciences Bld,
Jiao R, Dadachova E
doaj +2 more sources
Efficacy and Safety of Radioligand Therapy with Actinium-225 DOTATATE in Patients with Advanced, Metastatic or Inoperable Neuroendocrine Neoplasms: A Systematic Review and Meta-Analysis [PDF]
MedicinaBackground and Objectives: Peptide receptor radionuclide therapy (PRRT) using radiopharmaceuticals labelled with Lutetium-177 is currently a therapeutic option for patients with advanced neuroendocrine neoplasms overexpressing somatostatin receptors ...
Alessio Rizzo +9 more
doaj +2 more sources
PSMA-Targeting Radioligand Therapy in Prostate Cancer
healthbook TIMES. Oncology HematologyRadioligand therapy targeting prostate-specific membrane antigen (PSMA) represents a significant advancement in the treatment of metastatic prostate cancer.
Michael Wissmeyer, Magdalena Kulgawczuk
doaj +2 more sources
A proof-of-concept study of personalized dosimetry for targeted radioligand therapy using pre-treatment diagnostic dynamic PET/CT and Monte Carlo simulation [PDF]
Frontiers in OncologyPurposeTheranostics integrates diagnostic imaging (e.g., 18F-PSMA-1007 PET) with targeted radioligand therapy (TRT; e.g., 177Lu-PSMA-617), but personalized dosimetry remains challenging due to complex dose calculations.
Thanh Tai Duong +8 more
doaj +2 more sources
Radioligand therapy of metastatic castration-resistant prostate cancer: current approaches [PDF]
Radiation Oncology, 2018 Prostate Cancer is the forth most common type of cancer. Prostate-specific membrane antigen (PSMA) is anchored in the cell membrane of prostate epithelial cells.
Zool Hilmi Awang +2 more
doaj +3 more sources
Radioligand Therapy in Cancer Management: A Global Perspective. [PDF]
Cancers (Basel)Radioligand therapy (RLT) is a targeted treatment modality that combines a tumour-specific ligand with a therapeutic radionuclide. Once administered, the radiopharmaceutical binds selectively to cancer-associated targets, delivering cytotoxic radiation directly to tumour cells while sparing surrounding tissues.
Ninatti G, Lee ST, Scott AM.
europepmc +2 more sources